XML 25 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Consolidated Statements of Cash Flows - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (6,592,723) $ (4,996,069)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 6,811 5,972
Change in fair value of derivative liability, as restated (2,216,488) 189,000
Change in fair value of warrant liabilities, as restated 398,675
Amortization of debt discount and finance fees, as restated 2,123,049 377,384
Gain on marketable securities (4,970)
Change in fair value of marketable securities (71,568)
Accrued interest settled with common stock 294,927
Loss on settlement of notes payable and convertible notes payable, as restated 477,221 1,795,652
Fair value of freestanding instruments in excess of proceeds, as restated 189,912
Gain on settlement on accounts payable (328,687)
Gain on forgiveness of Paycheck Protection Program (73,007)
Stock-based compensation, as restated 181,960 237,547
Changes in operating assets and liabilities:    
Accrued interest income (14,901)
Prepaid expenses 46,675 (156,282)
Accounts payable and accrued expenses 166,115 (382,881)
Accounts payable and accrued expenses - related parties (12,054) 12,500
Accrued interest payable, as restated 110,453 18,378
Accrued interest payable - related parties (98,135) 51,188
Other assets 6,480
Change in operating lease asset and liabilities 16,001 (5,693)
Net cash used in operating activities (5,581,147) (2,666,411)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Investment in marketable securities (2,998,572)
Proceeds from disposition of marketable securities 187,895
Purchase of equipment (19,046)
Net cash used in investing activities (2,829,723)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from issuance of common shares and exercise of warrants, as restated 9,995,513
Proceeds from note payable-related party 50,000
Repayment of note payable-related party (685,473) (50,000)
Proceeds from convertible notes payable, as restated 3,935,000 550,715
Proceeds from notes payable and warrants, as restated 50,000
Payment for finance costs related to convertible note payable, as restated (345,000) (17,363)
Payment of convertible note payable (334,444)
Net cash provided by financing activities 2,570,083 10,578,865
Net change in cash and cash equivalents (5,840,787) 7,912,454
Cash and cash equivalents, beginning of period 8,417,203 504,749
Cash and cash equivalents, end of period 2,576,416 8,417,203
Cash paid for:    
Interest 164,807 39,201
Supplemental non-cash financing activities:
Common stock issued for conversion of accrued interest, as restated 16,340
Common stock issued upon conversion of convertible debt and exercise of related warrants, as restated 2,697,849 1,199,916
Common stock issued for exercise of warrants with settlement of notes payable, as restated $ 2,153,124
Common shares issued for dividends on and conversion of Series A convertible preferred stock, as restated 402,064
Warrants issued for financing fees, net of issuance fees of $8,727 and $0, respectively, as restated $ 90,816 $ 14,662
Reclassification of fair value of warrant liabilities to equity, as restated 881,553
Initial recognition of right of use asset and liability $ 365,556